Redirecting to LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
LG Chem Life Sciences
LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
Tuesday, February 23, 2021 10:00AM IST (4:30AM GMT)
First-In-Human Study Targeting the Endothelial Cell-expressed Adhesion Molecule VAP1
Nanjing, China & Seoul, South Korea & Cambridge, Mass., United States:
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
December 18, 2020 GMT
TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group ’s healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, jointly announced that they have entered into a strategic collaboration agreement for joint research and development of the innovative drugs in the target fields of oncology and inflammatory diseases.
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma, and share the research outcomes in both J